- After divesting its surgical products, the company has two main businesses left, the ESS and IGB business.
- We are quite optimistic about their ESS business as the company has just introduced a much better version of its OverStitch.
- However, its intragastric balloons’ business, good for one-third of revenues could be under threat from competition developing adjustable balloons.
- Company finances are also pretty bleak.
A Serious Threat Is Emerging To Apollo Endosurgery’s IGB Business
June 6th, 2019 · No Comments